17. The treatments on the way
Sources for this sheet (13)
- Tulisokibart — MSD — the phase 3 ATLAS-UC study meets its primary endpoint in ulcerative colitis (22 June 2026)
- Tulisokibart — ARES-CD phase 3 trial in Crohn's disease, 1,200 patients, primary completion 30 October 2028 (NCT06430801)
- Duvakitug — Sanofi and Teva — RELIEVE UCCD phase 2b maintenance results over 44 weeks (17 February 2026)
- Afimkibart — NCT06589986
- Afimkibart — NCT06819891
- Icotrokinra — ICONIC-UC phase 3 placebo-controlled trial, 896 patients with ulcerative colitis, enrolment complete, primary completion 14 January 2028 (NCT07196748)
- Icotrokinra — Phase 2b/3 placebo-controlled trial in Crohn's disease, 1,092 patients, primary completion 19 September 2028 (NCT07196722)
- Icotrokinra — FDA — Icotyde (icotrokinra), approved 17 March 2026 for plaque psoriasis (application NDA 220149)
- Skyrizi: subcutaneous induction — AbbVie — FDA approves the subcutaneous induction regimen for Skyrizi in Crohn's disease (23 October 2026)
- JNJ-4804 (Tremfya + Simponi) — Johnson & Johnson — phase 2b DUET-CD and DUET-UC presented at DDW (5 May 2026)
- Obefazimod — Abivax — phase 3 ABTECT maintenance results, 580 responders followed for 44 weeks (1 June 2026)
- Omilancor — Phase 2 placebo-controlled trial in ulcerative colitis, 198 patients, completed December 2020 (NCT03861143)
- Omilancor — Phase 2 trial in Crohn's disease, terminated in 2022 with 27 patients: « Decision of Landos Biopharma (not related to safety or efficacy) » (NCT03870334)
Download the image
